Pronađeno: 1-5 / 5 radova

Autori: Herbst Roy S

>> Filter: Samo Article i Review

>> Sve godine

Naslov IMpower110: Updated OS Analysis of Atezolizumab vs Platinum-Based Chemotherapy as First-Line Treatment in PD-L1-Selected NSCLC (Meeting Abstract)
Autori Herbst Roy S ... Andric Zoran G  ... (broj koautora 20) 
Info JOURNAL OF THORACIC ONCOLOGY, (2021), vol. 16 br. 3, Suppl. S, str. S224-S225
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 (Meeting Abstract)
Autori Herbst Roy S ... Andric Zoran G  ... (broj koautora 21) 
Info SWISS MEDICAL WEEKLY, (2020), vol. br. , Suppl. 247, str. 31S-32S
Projekat F. Hoffmann-La Roche, Ltd.Hoffmann-La Roche
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC (Article)
Autori Herbst Roy S ... Andric Zoran G  ... (broj koautora 22) 
Info NEW ENGLAND JOURNAL OF MEDICINE, (2020), vol. 383 br. 14, str. 1328-1339
Projekat Roche HoldingGenentech; IMpower110 ClinicalTrials.gov number [NCT02409342]
Ispravka Web of Science   Članak   Elečas   Rang časopisa   Citati: Web of Science   Scopus  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Impower110: Interim Overall Survival (OS) Analysis of a Phase Iii Study of Atezolizumab (Atezo) Monotherapy Vs Platinum-Based Chemotherapy (Chemo) as First-Line (1L) Treatment in PD-L1-Selected NSCLC (Meeting Abstract)
Autori Herbst Roy S ... Andric Zoran G  ... (broj koautora 20) 
Info JOURNAL FOR IMMUNOTHERAPY OF CANCER, (2020), vol. 8 br. , Suppl. 1, str. A1-A1
Ispravka Web of Science   Članak   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
Naslov Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study (Meeting Abstract)
Autori Herbst Roy S ... Andric Zoran G  ... (broj koautora 20) 
Info ANNALS OF ONCOLOGY, (2019), vol. 30 br. , Suppl. 11, str. 62-63
Projekat F. Hoffmann-La RocheHoffmann-La Roche
Ispravka Web of Science   Elečas   Rang časopisa   Citati: Web of Science  
facebook sharing button
twitter sharing button
linkedin sharing button
gmail sharing button
copy sharing button
>> Sve godine

Ispis zapisa u formatu:TXT | BibTeX